Belatacept for the prevention of organ rejection in kidney transplantation
For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 87
Referral date 01 July 2009
Topic area
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Paul Cooney
Executive Lead: Peter Littlejohns
Project manager: Kate Moore
Technical Lead: Joao Vieira

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Following on from information provided to NICE by the company in August 2019 the appraisal of Kidney transplantation – belatacept was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
26 February 2016 Discontinued. For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481

For further information on our processes and methods, please see our CHTE processes and methods manual